Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 626

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 626
---
CA closes one month later than the expected date; (c)a decrease of 41% in the share -basedincentives that was recorded in the year ended June30, 2024, if the discount rate used to discount the flows (31,83%) increases by 20% (discount rate of 38,20%), and an increase of 79% in the shared -basedincentives, if the discount rate used to discount the flows decreases by 20% (discount rate of 25,47%); F-121

Notes to Combined Financial Statements (Amounts in US Dollars, except otherwise indicated) 14. Shared-based incentives (cont.) (d)an increase of 34% of the share -basedincentives that was recorded in the year ended June30, 2024, if the volume of sales units increases by 10% compared to the estimated values in each year, and a decrease of 34% of the shared -basedincentives if the volume of sales units decreases by 10% compared to the estimated values in each year; (e)an increase of 20% of the share -basedincentives that was recorded in the year ended June30, 2024, if the value of the share on the market is 20% higher than that calculated through the fair value, and a decrease of 20% of the shared -basedincentives if the value of the share on the market is 20% lower than that calculated through the fair value. Accounting Treatment of Fair Value During the reporting period ended June 30, 2024, an expense of $1,226,867 was recognized in connection with the CEO’s share -basedcompensation plan that was granted after year -end. The service inception date for the CEO award for purposes of computing the compensation charge in the period ended June30, 2024 was in 2021, as per the consultancy agreement signed between Heritas S.A.U. and the CEO mentioned above. The amount is reflected in the income statement under General and Administrative Expenses and corresponds to an increase in the Share Premium within equity. See Note 2.17 for further information. The overall fair value of the award determined at the grant date was $ 1,943,847. As of June 30, 2023, the non -marketconditions affecting the grant were not expected to be met, so the amount of equity instruments that could eventually be vested was zero and therefore, it was not